


36th Stop TB Partnership Board Meeting

Global Fund


26th March 2023





Yes!
We can end
TB






GC7 Allocations & Application windows


GC7 Allocations by disease

- With the slightly higher resource envelope and the new global disease split, the amounts of funding allocated for 2023-2025 compared to 2020-2022 are:
 - \$152.6 million for HIV
 - **\$154.2 million more for TB**
 - \$111.2 million more for malaria
- An additional **US\$ 82 million in Catalytic Funding (Matching Funds)** has been allocated to select countries to “Find and successfully treat the missing people with drug-susceptible TB and drug-resistant TB.




Allocations to 20 GF TB Priority countries

Tuberculosis Allocation: 20 Priority countries



- The top 20 TB priority countries have aggregate allocations of over **US\$1.7 billion** in GC7.
- This corresponds to an **increase of 8.4%** and represents **71% of total TB funding**.
- 16 out of the 20 priority countries have an increased allocation in GC7.

Global Fund Application Windows



Data as of 10 March 2023

- Approximately 136 allocation applications are expected in 2023. The first applications for GC7 are expected later this month.
- Over 50% of funding applications are expected in window 2 (May 2023).
- Continued partner support will be critical for the smooth review of good quality requests for funding

TB Program Essentials: Improving quality and innovations:

1. TB Screening & Diagnosis




- Systematic screening using CXR +/- CAD
- Rapid molecular assays as first diagnostic test
- Testing for at least rifampicin resistance in bacteriologically confirmed TB
- Efficient TB diagnostic networks

2. TB Treatment & Care



- Child friendly formulations, 4-month regimen for non-severe DS-TB in children
- Shorter all-oral regimens for DR-TB
- People-centered support for treatment completion

3. TB Prevention



- TB Preventive Therapy available for all eligible people: PLHIV, children, eligible household contacts of people with bacteriologically confirmed TB.
- Shorter TB Preventive Therapy regimens

4. TB/HIV Collaborative Activities




- All PLHIV with active TB started on ART early as per recommendations

5. Cross-cutting areas




- Real-time digital case-based TB surveillance
- Private sector engagement
- Decentralized, community & home-based people centered services
- Human rights & gender-responsive programming



Portfolio Financial Absorption


In-country absorption for 5th replenishment IPs: IPs across all grant components achieved >80% absorption.



Data source: GOS extract (as of 09-Nov-2022).
Notes: Expenditure data as reported in GOS and reflecting the current status of Global Fund PU and PUDR validation and LFA verification
Analysis by DASH team

Latest in-country absorption for TB IPs:


TB IPs in the 6th replenishment are absorbing funds at a lower rate than the overall portfolio and also absorbing less than they were in the 5th replenishment



Data source: GOS extract (as of 09-Nov-2022).

Notes: Expenditure data as reported in GOS and reflecting the current status of Global Fund PU and PUDR validation and LFA verification

Analysis by DASH team




COVID-19 Response Mechanism & Pandemic Preparedness

C19RM 2021 Investments in Mitigation

A total of US\$176M was invested in TB Mitigation under C19RM 2021


- Of the US\$3,456 million awarded (including recommendations for Board approval), **US\$411 million (12%) is invested in mitigating the impact of COVID-19 on HIV, TB and malaria programs.**
- A total of **US\$176M (42%)** of C19RM was invested in TB Mitigation.
- Countries have shown increased demand for **digital chest X-rays, and multi-diseases platforms, including True Nat** which are not only critical for TB but important for **systems strengthening**

C19RM 2021 Awards in Mitigation



Analysis of TB Investments under C19RM

20 TB Priority countries



- An analysis on direct & indirect TB investments under C19RM was conducted in the 20 priority countries in 2022.
- The analysis found that **\$97M was invested directly for TB mitigation** and an **additional \$67M (42%)** could be found in other COVID-19 modules including case management, Infection Prevention & Control and lab strengthening.
- TB needs to remain a **priority for the C19RM** and shifts to **Pandemic Preparedness** due to the fact **TB was heavily impacted, kills more than other diseases and infrastructure for TB will be key for the next pandemic.**


C19RM Portfolio Optimization Wave 1:

TB Mitigation

- A total of **US\$133 million** has been awarded to **TB Mitigation**. Requests for integrated screening and testing are submitted under the TB mitigation category while contributing to strengthening multi-disease lab systems and diagnostics networks.
- **Drill down of investments in TB mitigation of US\$133 million composed by:**
 - ✓ **US\$54 million (41%)** for Digital X-rays
 - ✓ **US\$33 million (25%)** for testing machines (GeneXpert & TrueNat), both contributing to integrated multi-disease diagnostic platforms.
 - ✓ **US\$46 million (34%)** is targeted to TB testing consumables and other supporting investments.

C19RM Portfolio Optimization Awards in TB Mitigation (US\$ million)

- TB Testing consumables (cartridges, chips) & Other investments
- Integrated screening (Digital X-rays/AI)
- Integrated Testing (Truenat/GX)



*Other TB investments include **Mobile Testing Vans, mounted X-ray machines** and **campaign costs**.

Thank you!



The Global Fund to Fight
AIDS, Tuberculosis and Malaria

+41 58 791 1700
theglobalfund.org